Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds.
Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds.
复制标题
A1C 和空腹血糖水平与美国人群糖尿病视网膜病变患病率的关联:对糖尿病诊断阈值的影响。
DOI:
10.2337/dc09-0440
复制
发表时间:
2009-11
期刊:
影响因子:
16.2
通讯作者:
Saaddine JB
中科院分区:
文献类型:
--
作者:
Cheng YJ;Gregg EW;Geiss LS;Imperatore G;Williams DE;Zhang X;Albright AL;Cowie CC;Klein R;Saaddine JB
To examine the association of A1C levels and fasting plasma glucose (FPG) with diabetic retinopathy in the U.S. population and to compare the ability of the two glycemic measures to discriminate between people with and without retinopathy. This study included 1,066 individuals aged ≥40 years from the 2005–2006 National Health and Nutrition Examination Survey. A1C, FPG, and 45° color digital retinal images were assessed. Retinopathy was defined as a level ≥14 on the Early Treatment Diabetic Retinopathy Study severity scale. We used joinpoint regression to identify linear inflections of prevalence of retinopathy in the association between A1C and FPG. The overall prevalence of retinopathy was 11%, which is appreciably lower than the prevalence in people with diagnosed diabetes (36%). There was a sharp increase in retinopathy prevalence in those with A1C ≥5.5% or FPG ≥5.8 mmol/l. After excluding 144 people using hypoglycemic medication, the change points for the greatest increase in retinopathy prevalence were A1C 5.5% and FPG 7.0 mmol/l. The coefficients of variation were 15.6 for A1C and 28.8 for FPG. Based on the areas under the receiver operating characteristic curves, A1C was a stronger discriminator of retinopathy (0.71 [95% CI 0.66–0.76]) than FPG (0.65 [0.60 – 0.70], P for difference = 0.009). The steepest increase in retinopathy prevalence occurs among individuals with A1C ≥5.5% and FPG ≥5.8 mmol/l. A1C discriminates prevalence of retinopathy better than FPG.
登录
查看更多内容
影响因子:
120.7
作者:
Davidson, MB;Schriger, DL;Lorber, B
通讯作者:
Lorber, B
影响因子:
3.5
作者:
Holmes, Earle W.;Ersahin, Cagatay;Kahn, Stephen E.
通讯作者:
Kahn, Stephen E.
影响因子:
4.2
作者:
Wong, TY;Klein, R;Shea, S
通讯作者:
Shea, S
影响因子:
168.9
作者:
Wong, Tien Y.;Liew, Gerald;Shaw, Jonathan
通讯作者:
Shaw, Jonathan
影响因子:
16.2
作者:
Sacks DB;Arnold M;Bakris GL;Bruns DE;Horvath AR;Kirkman MS;Lernmark A;Metzger BE;Nathan DM;National Academy of Clinical Biochemistry;Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry
通讯作者:
Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry